Emcure completes acquisition of remaining 20.42% in Zuventus

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+7.4%Reaction day

₹1336.80

prior close

₹1350.40

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%+7.3% vs market

Pharmaceuticals peers, median of 154sector-0.3%+7.7% vs sector

On the reaction day the stock moved 7.3 pts more than Nifty Smallcap 250 and 7.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+1.6

15m

+2.1

30m

+2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+7.4+0.1+7.3-0.3+7.7

Next day

+5.2+0.2+5.0-0.8+6.0

+3.2-0.3+3.5-1.1+4.3

+4.6-0.0+4.6-0.4+5.0

+6.2+0.6+5.7-0.1+6.3

+2.5+0.3+2.2-0.9+3.3

+2.2+0.2+2.0-1.3+3.5

15d

-0.7+1.9-2.6-1.5+0.9

-0.7+0.3-1.0-2.0+1.3

+3.8-5.3+9.1-6.3+10.1

+14.0-1.3+15.4-5.5+19.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure Pharmaceuticals acquired 4,095,180 shares of Zuventus Healthcare, representing the remaining 20.42%, for Rs 7,249 million in cash. The shares have been credited to Emcure's demat account, taking ownership to 100%. Zuventus reported FY2025 turnover of Rs 10,798.99 million and profit after tax of Rs 1,347.82 million. This was a related-party purchase from individual shareholders.

Likely market impact

Emcure gains full ownership and all earnings from Zuventus, but faces a Rs 7.249 billion cash outflow and related-party transaction risk.